MRSA treatment

As we are well aware here , methicillin-resistant staph (MRSA) infections are very common in the community. We have had very good success overall with trimethoprim/sulfa (TMP/SMX), though for deep-seated infections, I have prescribed linezolid (which is very expense, >$100/pill, and requires a prior approval). So, being strongly prior-approval averse, I was impressed with a Swedish trial showing non-inferiority between TMP/SMX plus rifampin and linezolid (see MRSA tmpsmx rifamp as good J Antimicrob Chemo 2014 in dropbox, or doi:10.1093/jac/dku352). Study publically-funded. Details:

--150 patients (ave age 69, 68% male, 93% hospitalized for infection but of those 31% were elective admission), most with significant comorbidities (63% cardiovasc,17% pulm, 20% renal, 25% cancer…) given either TMP/SMX DS tid plus rifampin 600 daily vs linezolid 600 bid
--all had had sensitivity testing and found to be susceptible to all of the meds prior to randomization
--most had deep-seated infections, though 30% had “skin and soft tissue infection”
--median duration of therapy 12 days
--on intention-to-treat analysis, no difference (75% in linezolid and 79% with TPM/SMX plus rifampin were cured on assessment at 6 weeks). For per-protocol analysis, also no difference (82% in linezolid and 88% with TPM/SMX plus rifampin were cured on assessment at 6 weeks). No difference by type/severity of infection, mortality.
--adverse reactions were common in both groups (66%), with serious adverse events in 15 pts with linezolid and 16 on combo regimen; also nonsignificant difference in adverse reactions directly attributable to linezolid (4) and combo (9)

So, potentially useful study. The vast majority of patients with MRSA seen as outpatients here respond well to TMP/SMX alone, and I would not change that. Though, before doing that in other areas, it would be useful to know community-based sensitivities of MRSA, since we do not know the patient’s bacterial sensitivities prior to starting therapy, and would only use TMP/SMX if low level of community resistance (I would guess reasonable cutoff would be around 15%, esp if the infection is not so severe). However, for patients who have more severe skin infections (and I have gone through the painful prior-approval process a couple of times for linezolid), it seems reasonable to me to try TMP/SMX plus rifampin (watching for drug-drug interactions, esp with rifampin) and follow the patient closely

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more